MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Disease-modifying strategies"

  • 2016 International Congress

    Multi-modal recruitment strategy leads to expeditious enrollment in STEADY-PD III

    B.L. Greco, T. Simuni, J. Lowell, K.C. Hodgeman, S. Sharma, C.A. Marshall, J. Denmark, W. Galpern, J.L. Goudreau, C. Meuiner, C. Sia, C.A. Thomas, D. Young, K.M. Biglan (Rochester, NY, USA)

    Objective: To review a successful multi-modal recruitment strategy in a clinical trial of early untreated PD patients. Background: STEADY-PD III is a multicenter NINDS funded…
  • 2016 International Congress

    Deep brain stimulation in early stage Parkinson’s disease: Is it disease modifying?

    M.L. Hacker, M. Turchan, J. Tonascia, P.E. Konrad, T.L. Davis, J.S. Neimat, F.T. Phibbs, A.L. Sternberg, D.M. Shade, L.T. Drye, D. Charles (Nashville, TN, USA)

    Objective: To examine patterns of motor symptom worsening in the 2 years following deep brain stimulation (DBS) in early stage Parkinson's disease (PD). Background: Although…
  • 2016 International Congress

    Evaluation of regional changes in striatal DAT binding in a progressing Parkinson’s disease (PD) cohort: Lessons for imaging biomarker assessment in disease-modifying therapeutic trials

    J.P. Seibyl, D. Jennings, K. Marek (New Haven, CT, USA)

    Objective: To evaluate subregion-dependent striatal changes in dopamine transporter (DAT) binding using 123-I Ioflupane SPECT in PD participants in the Parkinson Progression Marker Initiative (PPMI)…
  • 2016 International Congress

    Fifteen years of clinical trials in Huntington’s disease: Too many clinical trial failures

    A.M. Travessa, F.B. Rodrigues, T.A. Mestre, C. Sampaio, J.J. Ferreira (Lisboa, Portugal)

    Objective: To investigate the trends in Huntington's disease (HD) therapeutic development by analyzing interventional clinical trials publicly registered for the last 15 years. Background: Like…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley